This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Specialty pharmacy experts and key opinion leaders gathered at Asembias AXS25 Summit and discussed critical insights in interviews with Pharmacy Times.
A recent study highlights the promising immune response and safety of the Arexvy vaccine in lung transplant recipients, crucial for preventing RSV infections.
Abemaciclib and ribociclib have various risks and benefits in treating early breast cancer, highlighting the importance of patient-provider communication.
Plozasiran shows promise in reducing cholesterol and triglyceride levels in patients with mixed hyperlipidemia and other harmful conditions, addressing significant cardiovascular risks.
Abigail Thomas, PharmD, and Lee A. Kral, PharmD, discuss the evolving role of psilocybin-assisted therapy in palliative care, highlighting current evidence, safety concerns, and how pharmacists can guide patient selection, manage drug interactions, and support education as the therapy moves closer to clinical use.
Jennifer Guthrie, RPh, district leader at CVS pharmacy describes the different medications to treat allergy symptoms and highlight how CVS stands out when addressing patients needs.
In clinical trials, the dihydroergotamine (DHE) nasal powder had favorable safety profiles and rapid pain relief in patients with migraine with or without aura.
Explore the latest advancements in treating transplant-ineligible multiple myeloma, highlighting new therapies and clinical trial outcomes for improved patient care.
A phase 1b study demonstrated that continuous subcutaneous infusion of low-dose lenalidomide in patients with relapsed or refractory (R/R) multiple myeloma achieved promising efficacy with significantly reduced hematologic toxicity compared to conventional oral dosing.
Research reveals that children face significant long-term health risks, including kidney, gastrointestinal, and cardiovascular issues, after COVID-19 infection.
Ronna Hauser, PharmD, senior vice president of policy and pharmacy affairs at NCPA, discussed concerns the association has with the implementation of the Medicare Drug Price Negotiation Plan
New research highlights the long-lasting effectiveness of mRNA COVID-19 vaccines, showing sustained B-cell and antibody responses in health care workers over 3 years.
The announcement could ease the burden of prior authorizations on patients, which can cause unnecessary delays for patients receiving prescriptions and serious complications.
Although most health care professionals agree that patients do not need prescriptions for chronic diseases during end-of-life care, patients often receive them anyway.
Children who received antibiotics between birth and 2 years of age were more likely to develop food allergies, allergic rhinitis, and asthma, but not neurodevelopmental conditions.
Multiple phase 3 clinical trials demonstrated dupilumabs (Dupixent; Regeneron, Sanofi) effectiveness in reducing hives and itch in patients with chronic spontaneous urticaria compared with placebo.
The findings suggest a potentially elevated risk of vision impairment with semaglutide (Ozempic, Wegovy; Novo Nordisk) use compared to other weight loss and diabetes medications.
Lepodisiran, a small interfering RNA, demonstrated cholesterol-lowering effects at 16-mg, 96-mg, and 400-mg doses, with the highest dose being the most effective.
At 28 to 179 days, COVID-19 infection in patients with preexisting chronic kidney disease (CKD) was associated with an increased risk of composite kidney events.
SOC emphasizes adaptability and individual professional judgment without compromising quality as individuals are held to the standard and expertise of their practice area
Huntington disease (HD) has no curative treatments, therefore, there is a great need for therapies that can reduce or slow the progression of symptoms.
The HERCULES trial demonstrates tolebrutinib's potential to slow disability progression in non-relapsing secondary progressive multiple sclerosis, offering a new treatment option for patients with limited therapeutic choices.
Small changes in blood pressure and pulse were shown in patients of all ages, and the authors suggested that these are monitored carefully in patients being treated for ADHD.
Tirzepatide-treated patients with chronic kidney disease (CKD), obesity, and heart failure with preserved ejection fraction (HFpEF) had improved renal function both by cystatin C and creatinine.
Glucagon-like peptide-1 (GLP-1) analogs demonstrate potential to address multiple pathological processes in Alzheimer disease, with promising early research suggesting cognitive improvements and potential for future treatment.
The new designations span both warm autoimmune hemolytic anemia and IgG4-related disease, 2 rare, immune-mediated conditions that burden patients due to a lack of available treatment options.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
73 
Let's personalize your content